Cargando…
Picking the Right Patient for Human Epidermal Growth Factor Receptor 3–Targeted Therapy in Platinum-Resistant Ovarian Cancer
Autores principales: | Schram, Alison M., Iasonos, Alexia, Hyman, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455312/ https://www.ncbi.nlm.nih.gov/pubmed/27998226 http://dx.doi.org/10.1200/JCO.2016.69.7169 |
Ejemplares similares
-
Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells
por: Granados, Michaela L., et al.
Publicado: (2015) -
Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
por: Rustin, G. J. S., et al.
Publicado: (2016) -
Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013) -
Epidermal Growth Factor Receptor: A Novel Target for Anticancer Treatment
por: Pandey, Manoj, et al.
Publicado: (2003) -
Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)